Itraconazole is named as a drug or biological intervention in 29 clinical trials in our USA, China, UK, India and Ireland trial registers, 19 of which are recruiting. Lead sponsors include AbbVie (4), Post Graduate Institute of Medical Education and Research, Chandigarh (3) and AstraZeneca (2). Registered phases: Phase 1, Phase 1/2, Phase 3 and Not applicable. Conditions studied include Healthy Volunteer; Healthy; Advanced Solid Tumors.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Healthy Volunteer | 4 |
| Healthy | 3 |
| Advanced Solid Tumors | 2 |
| Healthy Volunteers | 2 |
| Chronic Pulmonary Aspergillosis | 2 |
| Allergic Bronchopulmonary Aspergillosis | 2 |
| Fallopian Tube Cancer | 1 |
| Ovarian Cancer | 1 |
| Primary Peritoneal | 1 |
| Locally Advanced Solid Tumor | 1 |
| Metastatic Solid Tumor | 1 |
| Healthy Participants | 1 |
| Advanced Solid Tumor | 1 |
| Ovarian Neoplasms | 1 |
| Endometrial Neoplasms | 1 |
| Uterine Cervical Neoplasms | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| HER2-positive Advanced Solid Tumor | 1 |
| Bipolar Disorder | 1 |
| Metastatic Castration Resistant Prostate Cancer (mCRPC) | 1 |
| Small Cell Lung Cancer (SCLC) | 1 |
| Follicular Lymphoma (FL) | 1 |
| Advanced Malignant Neoplasm | 1 |
| Acute Myeloid Leukemia | 1 |
| Mixed Lineage Leukemia | 1 |
| Mixed Lineage Acute Leukemia | 1 |
| Hepatocellular Carcinoma | 1 |
| Pancreatic Ductal Adenocarcinoma | 1 |
| Biliary Tract Cancers | 1 |
| Esophageal Squamous Cell Carcinoma | 1 |
| Refractory or Relapsed Solid Tumors | 1 |
| Healthy Volunteers (HV) | 1 |
| Healthy Adult Subject | 1 |
| Healthy Adult Participants | 1 |
| Clinical Pharmacology | 1 |
| Lead sponsor | Trials |
|---|---|
| AbbVie | 4 |
| Post Graduate Institute of Medical Education and Research, Chandigarh | 3 |
| AstraZeneca | 2 |
| Eli Lilly and Company | 2 |
| DualityBio Inc. | 2 |
| Nuvalent Inc. | 1 |
| Novartis Pharmaceuticals | 1 |
| BioNTech SE | 1 |
| Aligos Therapeutics | 1 |
| Astellas Pharma Global Development, Inc. | 1 |
| Merck Sharp & Dohme LLC | 1 |
| Genentech, Inc. | 1 |
| Pfizer | 1 |
| Kura Oncology, Inc. | 1 |
| Qilu Pharmaceutical Co., Ltd. | 1 |
| MindRank AI Ltd | 1 |
| Sunshine Lake Pharma Co., Ltd. | 1 |
| Hansoh BioMedical R&D Company | 1 |
| Jiangsu Simcere Pharmaceutical Co., Ltd. | 1 |
| Advenchen Laboratories Nanjing Ltd. | 1 |
| Guangzhou Lupeng Pharmaceutical Company LTD. | 1 |
| Register | Itraconazole trials |
|---|---|
| Clinical trials in USA | 16 |
| Clinical trials in China | 12 |
| Clinical trials in UK | 4 |
| Clinical trials in India | 3 |
| Clinical trials in Ireland | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Itraconazole works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Itraconazole (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.